Genmab A/S (NASDAQ:GMAB) Stock Position Lifted by Fifth Third Bancorp

Fifth Third Bancorp increased its stake in Genmab A/S (NASDAQ:GMAB) by 16.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,151 shares of the company’s stock after purchasing an additional 6,015 shares during the period. Fifth Third Bancorp’s holdings in Genmab A/S were worth $825,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. EverSource Wealth Advisors LLC raised its holdings in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC grew its holdings in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after acquiring an additional 950 shares in the last quarter. Barclays PLC raised its stake in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after purchasing an additional 2,285 shares in the last quarter. Cromwell Holdings LLC lifted its stake in Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after acquiring an additional 2,496 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Genmab A/S during the fourth quarter worth $60,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Up 0.2%

GMAB opened at $22.86 on Tuesday. The stock has a market cap of $14.66 billion, a P/E ratio of 13.14, a P/E/G ratio of 2.65 and a beta of 0.96. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $28.56. The company has a fifty day simple moving average of $20.65 and a 200 day simple moving average of $20.74.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. The company had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, equities research analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

GMAB has been the topic of several recent analyst reports. Truist Financial dropped their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Sanford C. Bernstein cut Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, HC Wainwright reiterated a “buy” rating and set a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.